Serotonin Syndrome Market 2022
The Serotonin Syndrome Market report is an informative and in-depth analysis that offers a detailed overview of the industry, including recent developments and potential proportions of the demand for serotonin syndrome in terms of products and services.
According to the Market Research Future (MRFR) analysis, the Serotonin syndrome treatment Market is expected to hit $400 million, with CAGR estimated to rise by 2.3% during the forecast period.
Serotonin syndrome is a group of symptoms such as high body temperature, increased reflexes, anxiety, tremor, sweating, diarrhea, dilated pupils, etc. due to the use of serotonergic drugs. Severe complications, such as seizures and extensive muscle breakdown, can lead to death. The case of Libby Zion in 1984 is an example of death from serotonin syndrome. Serotonin syndrome is usually caused by a synergistic effect of two or more serotonergic drugs, commonly including serotonin norepinephrine reuptake inhibitor (SNRI), selective serotonin reuptake inhibitor (SSRI), monoamine oxidase inhibitor (MAOI), tricyclic antidepressants (TCAs), amphetamines, etc. Many drugs with a high potential to induce serotonin syndrome include dextromethorphan, buspirone, L-tryptophan, St. John's wort, metoclopramide, ondansetron, etc. There is no laboratory test supporting the diagnosis of serotonin syndrome.
Major Key Players:
global Serotonin Syndrome Market Key Players are Johnson Johnson, AstraZeneca Plc., Eli Lilly and Company, Forest Laboratories Inc., Ciron Drugs Pharmaceuticals Pvt. Ltd, GlaxoSmithKline plc., Merck Co., Inc., Pfizer, Inc. and Sanofi S.A, and others.
Segment Analysis
The global market for serotonin syndrome is segmented on drug treatment and end-users.
Based on drug treatment, the market for serotonin syndrome has been segmented as serotonin antagonists, supportive care(anti-hyperthermics, Muscle relaxants, the control of autonomic instability, antihypertensive, serotonin syndrome anesthesia and others).
Based on the end-users, the market has been segmented as hospitals, point of care, and others.
Regional Analysis
The global Serotonin Syndrome Market Key Players is segmented into North America, Europe, the Asia Pacific, and the Middle East Africa.
North America is further segmented into the United States and Canada. The United States accounts for the highest market share due to the increased use of medicines and higher expenditure on healthcare. The rapid consumer adoption of emerging technology and devices in the United States is also an essential factor driving the global market for serotonin syndrome.
Europe is the second-largest market due to high disposable incomes and increased awareness.
The Asia Pacific region is projected to have the most potential for the future and is predicted to be led by China and India.
The Middle East Africa market is dominated by Gulf nations, especially Saudi Arabia and the UAE. Africa's regions are projected to experience modest growth due to weak economic, political conditions, and low healthcare penetration.
About Market Research Future
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans conducts meet with the industry experts and industrial visits for its research analyst members.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 646 845 9312
